This topic contains a solution. Click here to go to the answer

Author Question: Two dimensions to generalizability are: a. construct validity and external validity b. ... (Read 36 times)

kellyjaisingh

  • Hero Member
  • *****
  • Posts: 540
Two dimensions to generalizability are:
 
  a. construct validity and external validity
  b. compensatory rivalry and external validity
  c. construct validity and compensatory rivalry
  d. none of the above

Question 2

Shortening the time between pretest and posttest or perhaps even offering cash payments to participants in an experiment are techniques that may be used to:
 
  a. limit diffusion
  b. decrease experimental mortality
  c. decrease the effects of instrumentation
  d. control threats to testing



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

macagn

  • Sr. Member
  • ****
  • Posts: 345
Answer to Question 1

a

Answer to Question 2

b




kellyjaisingh

  • Member
  • Posts: 540
Reply 2 on: Aug 13, 2018
Great answer, keep it coming :)


amit

  • Member
  • Posts: 364
Reply 3 on: Yesterday
:D TYSM

 

Did you know?

Multiple sclerosis is a condition wherein the body's nervous system is weakened by an autoimmune reaction that attacks the myelin sheaths of neurons.

Did you know?

Individuals are never “cured” of addictions. Instead, they learn how to manage their disease to lead healthy, balanced lives.

Did you know?

No drugs are available to relieve parathyroid disease. Parathyroid disease is caused by a parathyroid tumor, and it needs to be removed by surgery.

Did you know?

The Centers for Disease Control and Prevention has released reports detailing the deaths of infants (younger than 1 year of age) who died after being given cold and cough medications. This underscores the importance of educating parents that children younger than 2 years of age should never be given over-the-counter cold and cough medications without consulting their physicians.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library